Saframycin M x l is a DNA-binding antibiotic and antitumour agent produced by Myxococcus xanthus. It is a heterocyclic quinone, thought to be synthesized via the linear pepide intermediate AlaGlyTyrTyr. Analysis of 14-1 kb DNA sequence involved in saframycin production revealed genes for two large multifunctional peptide synthetases of 1770 and 2605 amino acids, respectively, and a putative 0-methyltransferase of 220 amino acids. The three ORFs read in the same direction and are separated by short non-translated gaps of 4 4 and 49 bp. The peptide synthetases contain two amino-acid-activating domains each. The first domain lacks two of the most conserved 'core' sequences, and the last domain is followed by a putative reductase functionality, not previously seen in peptide synthetases. Complementation tests showed that antibiotic-nonproducing mutant strains lacking one of the peptide synthetases secrete a substrate, presumably a modified amino acid precursor, that can be used by 0-methyltransferase-def icient mutant strains to synthesize saframycin M x l .
INTRODUCTION OCH,A

I
The Gram-negative myxobacteria grow in soil and have a complex life cycle with multicellular differentiation. Simiar to differentiating actinomycetes and bacilli, they . Myxococczts xantbzts produces saframycin Mxl (Irschick e t al., l988), a heterocyclic activity. Other saframycins were isolated from Streptomyces lavendztlae (Arai et al., 1977 (Arai et al., , 1980 . The saframycins bind covalently to DNA and inhibit DNA and RNA synthesis (Ishiguro et al., 1978 (Ishiguro et al., , 1981 ; Kishi e t al., 1984; Lown et al., 1982) . The N-heterocyclic quinone of saframycin Mxl (Fig. 1) is derived from two tyrosine molecules, and the side chain is derived from glycine and alanine (Trowitzsch-Kienast e t al., 1988) .
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The GenBank accession number for the sequence reported in this paper is 0002-0658 0 1996 SGM GACACAGTCC and 5'-ATGAATTCACAGCGTGTTGTC-GAGGATG 3' (the non-homologous tails containing EcoRI sites are underlined), and pAP93/8 (Pospiech et al., 1995) as template. Reaction buffer and Tag polymerase from Boehringer Mannheim were used. Thirty cycles of 30 s at 96 "C, 1 min at 55 "C, 1 min at 72 "C were performed in a Hybaid thermocycler (M WG-Biotech).
Gene disruption of M. xanthus DM504/15. pAP107-10 was introduced into M. xanthus DM504/15 by conjugation from E.
coli. An overnight culture of E. coli S17-1 containing pAP107-10, grown under kanamycin and ampicillin selection, was diluted 100-fold with LB medium without antibiotics and incubated for a further 6 h. Subsequently 1 x lo1' cells of this E. coli culture and 5 x lo8 cells of M. xanthzis DM504/15 (grown at 28 OC to a cell density of 2 x lo8 ml-' and preincubated for 10 min at 45 "C) were mixed, sedimented (SOOOg, 3 min), resuspended in 150 pl S45 medium and spotted onto S46 agar without antibiotics. After overnight incubation at 28 "C, cells were scraped off the agar and resuspended in 1 ml S45 medium. Portions (100 pl) were plated onto S46 plates containing 50 pg kanamycin ml-' and incubated for 6 d at 28 "C. Kanamycinresistant transconjugants, containing plasmids integrated into the genome via homologous recombination, were selected.
Biological assay (biotest) for saframycin M x l production. M. xanthus DM504/15 and its derivatives were grown for 5 d at 28 "C on S46 agar (20 ml per plate) without antibiotics. Agar plugs (3 mm in diameter) with single colonies were placed onto DST agar freshly overlaid with 10 ml 45 "C DST agar containing 100 pl of an overnight culture of Sarcina lutea. After overnight incubation at 30 "C, the inhibition zones of S. lutea were measured. This biological assay detected b 0.5 ng saframycin Mxl. Colonies of strain DM504/15 produce 10-25 ng saframycin Mxl and inhibition zones of 10-14 mm diameter; non-producing mutants did not inhibit the growth of S. htea.
Complementation test. M. xanthus mutant strains were grown for 3 d at 28 "C in S45 medium without antibiotics. Subse- HPLC analysis of saframycin Mxl production. S45 medium (20 ml) was inoculated with 1 ml cells from a -70 "C stock in 20 % (v/v) glycerol and incubated with shaking for 3 d at 28 "C. Then a second preculture in 20 ml S45 medium was inoculated with 5 YO of the first culture and incubated with shaking for 3 d
at 28 "C, after which 1.5 ml of the second culture was transferred to a 200 ml Erlenmeyer flask containing 50 ml Saf3 medium [containing, per litre: 3 g casein peptone, 32 g dextrin A-332, 2 g MgSO, .7H,O, 0.5 g CaC1,. 2H,O, 4 g sodium citrate, 50 g absorber resin XAD 11 80 (Rohm and Hass), pH 7.21. After 3 d shaking at 28 "C, 5 ml 5 % (w/v) casitone was added. After additional incubation for 3 d at 28 "C the absorber resin XAD 1180 was harvested on a polyester sieve (Satorius, and eluted with 20 ml 90% (v/v) 2-propanol by shaking for 30 min in 50 ml Falcon tubes at room temperature. The 2-propanol eluate was centifuged for 5 min and the clear supernatant was analysed by HPLC for its saframycin Mxl content. For reverse-phase HPLC analysis, the silica-based stationary phase Lichrospher 60 A RP-18 (5 pm; Merck) was used in a 12.5 cm column. A potassium phosphate buffer (2.5 mM, pH 3) acetonitrile gradient was the mobile phase. Saframycin Mxl was detected by absorption at 260 nm. Yields for strain DM504/15 were between 18 and 24 mg (1 culture)-'. The detection limit was 3 mg 1-' .
DNA sequencing. Double-stranded DNA fragments were cloned into pBluescript I1 SI<' and both strands were examined by DNA cycle sequencing with dye-labelled terminators (Sanger et al., 1977) and an Applied Biosystems automated sequencer (model 373A). Universal primer and oligonucleotide primers designed according to the newly obtained DNA sequences were used. The standard cycling conditions were 25 cycles of 96 "C for 20 s and 60 "C for 240 s. All reactions were performed in a Perkin-Elmer GeneAmp 9600 PCR system using the AmpliTaq DNA polymerase from Perkin-Elmer.
Computer analysis of DNA and protein sequences. The DNA sequences were assembled and analysed using software version 1.20 from Applied Biosystems and the UWGCG program package version 8.0 (Devereux e t al., 1984) .
RESULTS AND DISCUSSION
Sequence of three ORFs involved in saframycin M x l biosynt hesis
The sequence of saframycin biosynthesis genes was extended in both directions to cover 14.1 kb of DNA with an overall G + C content of 71 mol YO, typical for myxobacteria. Three ORFs with a codon usage typical for high-G + C genes were identified using the program CODONPREFERENCE (Fig. 2) . The three ORFs read in the same direction and are separated by short, presumably untranslated, regions of 44 and 49 bp (Fig. 2) . Each ORF is preceded by potential ribosome-binding sites upstream of the ATG start codons ( 
Putative peptide synthetases SafA and SafB
Both SafA and SafB contain two domains of approximately 520-600 amino acids resembling amino-acidactivating domains of known peptide synthetases. Highly conserved 'core' sequences, defined by , are clearly recognizable in all four domains (Fig. 3) .
The domain SafBl is unusual in that it lacks core sequence 5 (ATP-binding ; Pavela-Vrancic e t al., 1994a, b; Tohika et al., 1993) , has a poorly conserved core sequence 1 (unknown function) and has an unusually large spacing between the core sequences 1, 2 and 3 (Fig. 3) , 1988) . Therefore, SafB1, the first domain in the sequence, probably activates alanine, the first amino acid in the putative saframycin precursor peptide. The poor conservation or lack of core sequences 1 and 5 is unusual for peptide synthetases, but the related adenylate-forming enzymes also lack strict conservation of these sequences (Marahiel, 1992) .
Safl32, SafAl and SafA2 contain all six core sequences. A spacer motif is located upstream of SafAl (aa 165-172), the normal position for peptide synthetases not initiating a peptide chain (Stachelhaus e t al., 1995) . Downstream of SafA2, without an intervening spacer sequence, are 370 (Weckermann et a/., 1988) ; SrfA, surfactin synthetase (Cosmina e t a/., 1993). Perfectly conserved amino acids are printed in bold. The numbers on the left give the positions of the first amino acids shown; numbers between the amino acids indicate the distances between these sequences. The core sequences were defined by . synthetase from Anabaena sp. (Black & Wolk, 1994) ; EryAZ, pketoreductase domain of the polyketide synthetase involved in erythromycin biosynthesis of Saccharopolyspora erythraea (Donadio & Katz, 1992) ; Lys2, a-aminoadipate reductase of Saccharomyces cerevisiae (Morris & links-Robinson, 1991 -Robertson, 1991) . SafA2, HetM and Lys2 contain an NAD(P)H binding motif (Fig. 4) characteristic for diverse reductive enzymes. SafA2 is the first peptide synthetase amino-acid-activating domain with a putative reductase function but interestingly, Lys2 contains all six peptide synthetase core sequences in the correct order upstream of the NAD(P)H-binding motif, but with a different spacing (Morris & Jinks-Robertson, 1991) . 
SafA3 (2216)
The putative 0-methyltransferase SafC
SafC shows 51 Yo identity over its entire length to the 0-methyltransferase MdmC of the midecamycin producer Streptomyes mycarofaciens (Fig. 5) precursor secreted by the peptide-synthetase-deficient strain. Therefore, the peptide synthetases probably use methylated amino acid derivatives either as natural substrates or as alternative substrates. ( Kagan & Clarke, 1994) are also present in SafC (Fig. 6 ). Due to its high degree of similarity to S-adenosyldependent O-methyltransferases, SafC can be grouped in a class of enzymes catalysing O-methylations of small molecules (Kagan & Clarke, 1994) and may be responsible for one, two or all three O-methylation reactions necessary for the biosynthesis of saframycin Mxl (Fig. 1 ). 
Cross-f eed i ng experiments
The above s a f A , s a p and safC mutant strains were used for cross-feeding studies designed to detect the existence of diffusible saframycin Mxl precursors. Mixed culture of the s a f A and s a p mutant strains, presumably lacking peptide synthetase activity, did not result in antibiotic production. Mixed growth of either of these strains with the safC mutant strain resulted in a 4 mm inhibition zone, indicating a low but significant level of saframycin biosynthesis. The DM504/15 control gave an inhibition zone of 12 mm. When the safC mutant strain was grown near the s a f A or s a p mutant strain, antibiotic appeared near the former, indicating that the safC strain converted a
Conclusions
The two putative peptide synthetases SafB and SafA (Fig.  2) involved in saframycin Mxl biosynthesis contain two amino-acid-activating domains each, consistent with the hypothetical linear tetrapeptide structure of the saframycin precursor. The first domain, S a m l , probably responsible for activating the amino-terminal alanine, lacks the usually well-conserved peptide synthase core sequence 1, and the last domain, SafA3, has attached a putative reductase function, possibly involved in the modification of the carboxy-terminal tyrosine. Both of these domains represent new types of amino-acidactivating domains.
The targeted gene disruptions, together with the crossfeeding experiments, proved the involvement of the three sequenced ORFs in saframycin biosynthesis. The crossfeeding experiment using strains growing close together rather than mixed indicated that the putative 0-methyltransfrerase encoded by safC presumably modifies tyrosine before it becomes a substrate for the peptide synthetase. This, of course, has implications for the possible use of the saframycin peptide synthetase modules for the construction of recombinant peptide synthetases for the synthesis of new metabolites as pioneered by Stachelhaus et a/. (1995) .
